(212) 713-5336

Mind / Body Blog

Why a Helium Shortage Might Affect Your Psychiatric Care (Even If No One Mentions It)

Posted on April 13, 2026 by Maurice Preter MD

Why a Helium Shortage Might Affect Your Psychiatric Care (Even If No One Mentions It)

If you’re looking for a psychiatrist or neuropsychiatrist—especially in a place like Manhattan—you probably expect things to work smoothly.

Appointments are available. Testing is fast. Answers come quickly (ideally).

That’s the baseline.

So it can be confusing when something feels… slower than expected. A delay in getting an MRI. A referral that takes longer than it should. Extra back-and-forth where you thought things would be straightforward.

One of the reasons is the looming geopolitical supply shock causing a global helium shortage.

That might sound irrelevant. It’s not.

The Part No One Explains: Helium Runs MRI Machines

MRI machines need helium to function. It keeps their internal magnets at extremely low temperatures. Without it, they don’t work properly.

So when helium supply gets tight:

  • Fewer MRI slots are available
  • Machines go offline for maintenance more often
  • Imaging centers get backed up

This isn’t something most clinics advertise. But it affects how quickly you can get answers—especially if your care involves brain imaging.

Why This Matters in Psychiatry

Best case scenario, psychiatry is psychoanalysis and occasionally, short-term medication. Sometimes it is. But not always.

Especially a neuropsychiatrist—may recommend imaging to:

  • Rule out/visualize central nervous system structural disease  
  • Investigate cognitive or memory problems
  • Investigate unusual or treatment-resistant symptoms
  • Get a clearer picture before making big treatment decisions

If that imaging is delayed, everything else can slow down too.

That means:

  • Longer time to diagnosis
  • More uncertainty
  • Delayed treatment adjustments

From a patient perspective, that’s frustrating—especially if you’re already dealing with stress, anxiety, or cognitive concerns.

Why It Feels More Noticeable in Manhattan

In Manhattan, you’re used to speed.

You might be paying for concierge care. You expect:

  • Quick access
  • Coordinated services
  • Minimal waiting

So when something like an MRI takes longer than expected, it stands out.

What’s happening behind the scenes is simple:

  • Imaging centers are under pressure
  • Demand is high
  • Supply (helium) is down/inconsistent

Even very well-run practices can’t fully control that.

What You Might Actually Experience

You probably won’t hear “helium shortage” directly. Instead, it shows up like this:

  • “The earliest MRI appointment is next week instead of tomorrow”
  • “That facility is booked—let’s try another one”
  • “We’re waiting on imaging before making changes”

None of these sound dramatic. But together, they can make your care feel slower or less predictable.

What a Good Psychiatrist Does Differently

This is where the quality of your clinician really matters.

A strong psychiatrist or neuropsychiatrist won’t just rely on systems working perfectly. They’ll:

  1. Have Backup Options

They know multiple imaging centers, not just one.

  1. Avoid Unnecessary Testing

They won’t send you for an MRI unless it’s actually useful.

  1. Keep Things Moving

If imaging is delayed, they’ll still help you make progress where possible.

  1. Explain What’s Going On

Not in technical terms—but enough that you understand why something is taking time.

What You Can Do as a Patient

You don’t need to manage supply chains. But you can ask better questions.

If imaging is recommended, ask:

  • “How urgent is this?”
  • “Are there faster options?”
  • “Will this change the treatment plan right away?”

This helps you understand whether you’re waiting for something critical—or just being thorough.

The Bigger Reality: Even High-End Care Has Limits

It’s easy to assume that if you’re in a top-tier practice, everything is instant and seamless.

Most of the time, it is.

But medicine still depends on real-world systems—equipment, materials, logistics. And sometimes those systems get strained.

Helium is just one example.

Understanding that doesn’t lower the quality of your care. It just makes the process easier to navigate.

The Bottom Line

If something in your psychiatric care feels slower than expected—especially around imaging—it may not be poor management or lack of attention.

It could be something as simple (and as invisible) as a helium shortage.

What matters more is how your psychiatrist handles it.

Do they adapt?
Do they communicate clearly?
Do they keep your care moving forward anyway?

That’s the difference you should be paying attention to.

Posted in News | Tagged , , |

Threat, Deprivation, and the Architecture of the Mind

Posted on April 11, 2026 by Maurice Preter MD

Threat, Deprivation, and the Architecture of the Mind

Threat and neglect are not “stress” — they are distinct psychological forces that shape memory, identity, and attention. A neuropsychiatric analysis of their legacy.

Posted on April 11, 2026 by the PsychiatryNeurology.net Team

“Stress” is a word that obscures as much as it reveals. When clinicians and patients reach for it, they rarely distinguish between two fundamentally different classes of adverse experience: threat — the anticipation or reality of harm — and deprivation — the absence of expected care, emotional connection, or cognitive stimulation. These two dimensions carve different psychological landscapes, and their effects on how a person thinks, remembers, and relates are not interchangeable.

Adverse childhood experiences (ACEs) gain much of their predictive power precisely because they aggregate threat and deprivation into a single score. But from a clinical neuropsychiatry perspective, it is the quality of the adversity, not simply its quantity, that shapes adult cognition and emotional life. This article explores how threat and deprivation imprint themselves on the mind — its expectations, its memory, its capacity for attention — and why that distinction matters for treatment.

The Two Dimensions of Adversity

Research in developmental psychopathology has long argued for separating adversity into threat (physical abuse, domestic violence, events that activate the fear system) and deprivation (emotional neglect, institutional care, lack of responsive caregiving). These dimensions have different psychological consequences, different developmental timings, and different neural signatures.

Threat tunes the mind toward detection. It teaches that danger can arise without warning, that negative outcomes are probable, and that vigilance is necessary. The psychological residue is a set of expectancy biases: ambiguous situations are interpreted as menacing, neutral faces as hostile, quiet moments as a prelude to something terrible. Attention becomes captured by threat-related stimuli, and cognitive resources are chronically allocated to monitoring rather than to constructive thinking.

Deprivation tunes the mind toward muting. When emotional signals are not mirrored, when cognitive enrichment is absent, the psyche adapts by reducing reliance on the social environment. The result is often a flattened emotional range, a diminished inner vocabulary for feelings, and an autobiographical memory that lacks the vivid specificity that comes from having experiences reflected back by an attuned other. Rather than a mind on high alert, one finds a mind that has learned that its own interior is of no interest to the world.

Most people with significant adversity histories carry a combination of both. The dialectic between them — vigilance and numbness, reactivity and blankness — is itself a core clinical feature.

Cognition Under Threat: Attentional Capture and Rumination

When the mind has been shaped by threat, attention is not freely deployed; it is conscripted. The cognitive profile is not primarily one of “deficit” but of misallocation. Working memory becomes occupied with scanning for risk, replaying worst-case scenarios, and mentally preparing countermoves. What looks like forgetfulness is often a failure of encoding: the mind was elsewhere, tracking safety, when the information was presented.

This pattern is particularly visible in social cognition. An ambiguous remark from a colleague is rapidly interpreted through a threat-lens — criticism, exclusion, impending conflict — and the mind begins a loop of rumination that is difficult to interrupt. The subjective experience is one of mental fatigue, racing thoughts, and a pervasive sense of being unable to concentrate on what matters. But the underlying mechanism is not a broken attention system; it is an attentional system drafted into permanent surveillance duty.

Psychologically, this is maintained by core beliefs about the self and world — “I am in danger,” “Others cannot be trusted” — that were adaptive in the original environment but become maladaptive when threat is no longer present. The therapeutic task is not to argue with these beliefs but to help the mind register disconfirming information that is already available but automatically filtered out.

Cognition Under Deprivation: The Hollowed-Out Memory

In deprivation, the cognitive signature is different. Autobiographical memory often lacks episodic richness — events are recalled with few sensory details, little emotional texture, and a curious sense of distance, as if the memory belongs to someone else. This phenomenon, sometimes described as overgeneral memory, has been linked to early neglect and is thought to reflect a developmental absence: the child learned to truncate memory retrieval to avoid the pain of unmet emotional needs.

Semantic memory — the store of facts and knowledge — may be comparably thin if cognitive stimulation was lacking. But even when factual knowledge is intact, the subjective experience can be one of mental emptiness, difficulty generating thoughts, and a sense of being “blank” in conversation. This is not depression per se; it is a psychological apparatus that has withdrawn from the world of inner experience.

Emotionally, deprivation fosters a state of alexithymia — a difficulty identifying and describing one’s feelings — and often a pattern of depersonalization, where the self feels unreal. These are not mysterious symptoms; they are predictable consequences of a developmental history in which one’s emotional life was never named, validated, or met with curiosity.

The Intersection of Threat and Deprivation

In clinical practice, the pure-threat or pure-deprivation history is rare. More common is the patient who grew up with an unpredictably violent parent and an emotionally absent one — both threat and deprivation, often interwoven. The psychological result is a mind that oscillates between hyperarousal and emotional shutdown, that cannot rest but cannot truly connect.

This oscillation is easily mistaken for borderline personality organization or bipolar II, and often it is treated with algorithms developed for those conditions. But understanding the specific psychological architecture — what the mind learned to expect from threat, what it learned to give up on from deprivation — allows for a more coherent formulation. The panic is not random; it is the activation of a threat model. The emptiness is not a biological deficit; it is the silence left by unmet connection.

Memory Complaints as Psychological Phenomena

When a patient with an adversity history reports memory problems, neuropsychiatry has a dual responsibility: rule out neurological pathology, and interpret the complaint psychologically. The question is not only “Is the hippocampus intact?” but “What is your mind doing instead of encoding?”

For the threat-driven mind, encoding is interrupted by vigilance. For the deprivation-driven mind, encoding never fully engaged because the experience lacked the emotional significance that would mark it for retention. In both cases, memory complaints are real and disabling, but they are not — in most cases — signs of a neurodegenerative process. They are signs of a mind that was never fully free to attend to experience in the first place.

This reframing has therapeutic power. Patients often fear they are developing dementia. Understanding that their cognitive symptoms are the logical output of a psychological history — that their mind is not broken but adapted — can itself reduce secondary anxiety and open space for change.

Psychological Recovery: Not Repair, But Recalibration

The language of “healing” can be sentimental. A more precise framing is that the mind can be recalibrated — its predictions updated, its attention redirected, its inner life reanimated. This requires specific, often slow, psychological work.

For threat patterns: The intervention is exposure to safety that the mind can actually register. This sounds simple but is technically demanding, because the threat-biased mind filters safety out. Cognitive-behavioral techniques that train attention to non-threat cues, combined with repeated experiences of stable, non-punitive relationships, gradually adjust expectancy bias. The goal is not to eliminate alertness but to restore its proportionality.

For deprivation patterns: The work is about mentalization — learning to identify and label internal states in the presence of another mind that treats those states as real and worth exploring. Psychodynamic, mentalization-based, and emotion-focused therapies all target this capacity. The therapeutic relationship becomes the scaffold on which a richer inner life is built.

In both cases, improvement does not mean erasing the past. It means reducing the degree to which the past captures the present. A patient once described it as “the difference between being dragged by a current and seeing that the current is there.”

Clinical Implications for Neuropsychiatry

A dual-specialty framework is uniquely positioned to handle adversity-related cognitive complaints without falling into either pure biologism or pure psychologism. We can investigate neurological integrity — imaging, neuropsychological testing, EEG — while simultaneously exploring the psychological architecture: What did your environment teach you to expect? What did it teach you to ignore?

This integrated approach avoids the common error of treating threat- and deprivation-driven cognitive symptoms as ADHD or mild cognitive impairment without addressing the underlying psychology. It also avoids the opposite error of assuming that every cognitive complaint in an adversity-exposed patient is purely psychological, missing the real neurological comorbidities that can arise.

Frequently Asked Questions

Q: How do threat and deprivation differ from “stress”?
Stress is a nonspecific term that conflates experiences with fundamentally different psychological signatures. Threat activates fear and vigilance; deprivation involves the absence of expected care. Distinguishing them allows for more targeted formulation and treatment.

Q: Can you have both threat and deprivation in your history?
Yes. Most individuals with high ACE scores experienced both. The psychological presentation often involves an oscillation between hypervigilant and emotionally flat states, which can complicate diagnosis.

Q: If my memory problems are psychological, can they still improve?
Yes. As the mind reallocates its attentional resources — trading vigilance for engagement, emptiness for emotional connection — cognitive function often improves. The timeline varies, but the change is real and measurable.

Q: Is medication appropriate for these difficulties?
Medication may be helpful in reducing the intensity of anxiety or depressive symptoms that interfere with psychological work, but it does not directly recalibrate the psychological models shaped by threat and deprivation. An integrated approach is typically best.

Also of interest:

Depression in retired executives is a complex and multifaceted issue that affects a significant portion of this population.

Posted in Aging, epigenetics, Forensic Neuropsychiatry, Health, Psychiatry/Neurology | Tagged , , , , , , , , , , , , , , |

Concierge Psychiatry for High-Net-Worth Individuals: Private Psychiatrist Support During Stock Market Volatility

Posted on April 6, 2026 by Maurice Preter MD

Concierge Psychiatry for High-Net-Worth Individuals: A Targeted Alternative to Concierge psychiatrist Insurance-Based Mental Health Care

Corporate health insurance–based systems are designed for scale and standardization. They are not always well-suited to the needs of individuals operating in high-pressure, high-stakes environments.

Mental health care is a clear example of this mismatch. Long wait times, brief appointments, limited continuity, and administrative constraints can make it difficult to access timely, personalized support—especially during periods of stock market volatility or intense professional demand.

Concierge psychiatrist services and concierge neuropsychiatry have developed as alternatives to insurance-based models, offering a more direct, flexible, and individualized approach.

The Limits of Insurance-Based Mental Health Care

Corporate or insurance-based psychiatric care is structured around efficiency and cost control. This often results in:

  • Short, standardized appointment times
  • Limited availability of specialists
  • Fragmented care across multiple providers
  • Delays in scheduling
  • Administrative requirements that can affect privacy

For many individuals, this model is sufficient. However, for those managing significant financial exposure, leading organizations, or operating under continuous pressure, these constraints can become limiting.

Mental health concerns in this group are often situational, time-sensitive, and closely tied to external factors such as market conditions, leadership responsibilities, or complex personal dynamics. A more responsive model can be necessary.

Mental Health Under Stock Market Volatility

Periods of stock market volatility can create sustained psychological stress, particularly for individuals with substantial capital at risk.

Common patterns include:

  • Heightened anxiety linked to portfolio fluctuations
  • Sleep disruption during periods of uncertainty
  • Difficulty maintaining long-term decision frameworks
  • Increased reactivity to short-term market movements

These responses are not unusual. They reflect how the brain processes risk and uncertainty. However, without proper management, they can interfere with judgment and consistency.

A private psychiatrist who understands financial environments can help identify when normal stress responses begin to affect decision-making and implement strategies to stabilize cognitive performance.

What Concierge Psychiatry Offers

Concierge psychiatry operates outside of insurance-based systems. It is typically structured through a direct relationship between patient and physician, often via a retainer or membership.

This model allows for:

  • Flexible scheduling, including same-day or next-day access
  • Longer, more detailed consultations
  • Direct communication with the psychiatrist between visits
  • A consistent, ongoing relationship with a single provider

Because it is not constrained by insurance billing requirements, care can be adapted more precisely to the individual’s needs.

Concierge Neuropsychiatry: Expanding the Scope

Concierge neuropsychiatry builds on this model by incorporating a more detailed understanding of brain function and cognition.

This approach may include:

  • Assessment of attention, memory, and executive function
  • Evaluation of how stress impacts cognitive performance
  • Identification of early neurological changes when relevant
  • Integration of mental health treatment with performance-focused strategies

For HNW individuals, this can be particularly relevant in maintaining consistent decision-making capacity over time.

Why HNW Individuals Shift Away From Insurance-Based Care

  1. Responsiveness

In insurance-based systems, access is often delayed. In contrast, concierge psychiatry allows for faster intervention, which can prevent escalation of symptoms.

  1. Continuity

Insurance-based care may involve rotating providers or limited follow-up. Concierge models prioritize long-term relationships, allowing for deeper understanding of patterns and context.

  1. Privacy

Insurance systems require documentation and data sharing that may not align with the privacy expectations of some individuals. Concierge psychiatry reduces this administrative exposure.

  1. Contextual Understanding

A concierge psychiatrist working with HNW clients is more likely to be familiar with:

  • Investment-related stress
  • The psychological impact of stock market volatility
  • Leadership and governance pressures
  • Complex family or wealth structures

This context allows for more relevant and efficient care.

House Call Psychiatry as a Practical Option

House call services are a defining feature of many concierge practices. A concierge psychiatrist may meet patients in their home, office, or another private setting.

This approach offers:

  • Greater scheduling flexibility
  • Reduced need for travel or disruption
  • Increased discretion
  • A more controlled environment for discussion

House call psychiatry is often used when convenience or privacy is a priority, or when a patient is experiencing acute stress and prefers a familiar setting.

Decision-Making and Cognitive Stability

For individuals actively engaged in investing or leadership, mental clarity is directly tied to outcomes.

Under stress, predictable cognitive patterns can emerge:

  • Overweighting short-term losses
  • Reacting to recent market movements rather than long-term trends
  • Avoiding necessary risk during downturns
  • Becoming overconfident during recoveries

A private psychiatrist can help identify these patterns and develop strategies to maintain consistency. This may involve:

  • Structured decision frameworks
  • Techniques to manage emotional reactivity
  • Monitoring for early signs of cognitive fatigue

The goal is to support stable, rational decision-making even in uncertain conditions.

Burnout in High-Responsibility Roles

Burnout is common among individuals managing sustained responsibility, particularly when combined with financial exposure and market uncertainty.

Symptoms may include:

  • Persistent fatigue
  • Reduced concentration
  • Lower tolerance for stress
  • Disrupted sleep
  • Gradual decline in performance

Concierge neuropsychiatry approaches burnout by addressing both mental and cognitive factors. Interventions may include:

  • Adjustments to workload and recovery cycles
  • Sleep optimization
  • Stress management strategies
  • Medication when appropriate
  • Cognitive performance support

Because care is ongoing, changes can be monitored and adjusted over time.

Integration With Broader Advisory Structures

HNW individuals often work within a network of advisors. Concierge psychiatry can integrate into this structure when appropriate.

This may involve:

  • Coordination with primary care physicians
  • Alignment with executive coaching or performance advisory
  • Support for family governance or communication issues

The intent is not to replace other advisors, but to ensure mental health considerations are aligned with broader decision-making frameworks.

Family Applications

Concierge psychiatric services are often extended to family members. This can provide continuity across:

  • Adolescent mental health care
  • Family communication challenges
  • Stress related to wealth transitions
  • Major life events

A centralized approach can improve consistency while maintaining appropriate confidentiality for each individual.

Technology and Access

Concierge psychiatry typically includes secure telehealth options, allowing for continuity of care across locations.

Additional tools may include:

  • Structured mental health tracking
  • Cognitive assessments
  • Regular check-ins between appointments

These tools are used to support ongoing care rather than replace direct interaction.

When This Model Is Most Relevant

Concierge psychiatry may be particularly useful when:

  • There is significant exposure to stock market volatility
  • Professional roles involve high-stakes decision-making
  • Timely access to care is important
  • Privacy is a primary concern
  • There is a need for consistent, long-term psychiatric support

It is often used proactively, rather than only in response to acute issues.

Cost Structure

Concierge psychiatry is generally not covered by insurance and operates on a retainer or fee-for-service basis.

Costs reflect:

  • Increased access and availability
  • Longer appointment times
  • Continuity of care
  • Optional services such as house calls

For many HNW individuals, the decision is based on efficiency, access, and alignment with their overall approach to healthcare.

Conclusion

Insurance-based mental health systems are designed for broad access, but they may not provide the level of responsiveness, continuity, or discretion required by high-net-worth individuals.

Concierge psychiatry and concierge neuropsychiatry offer an alternative model—one that emphasizes direct access, individualized care, and integration with the realities of financial and professional life.

In periods of stock market volatility, this approach can help maintain emotional regulation, cognitive clarity, and consistent decision-making. Over the long term, it supports stability in environments where uncertainty is unavoidable.

Posted in News | Tagged , , , , , , |

When Depression Is Not a Primary Mood Disorder

Posted on March 12, 2026 by Maurice Preter MD

Clinical Neuroscience  ·  May 12, 2026

When Depression Is Not a Primary Mood Disorder

A landmark Danish cohort study tracked 17,711 patients over a decade and found that depression rises steadily in the years before Parkinson’s disease and Lewy body dementia — and cannot be explained by the distress of living with a chronic illness. The implications for how psychiatrists and neuropsychiatrists evaluate late-life depression are considerable.

PsychiatryNeurology.net Editorial TeamMay 12, 20268 min read

For most of its modern history, psychiatry has treated late-life depression as a diagnosis with a clear enough logic: aging involves loss — of function, of peers, of independence — and the brain responds accordingly. When an older patient presents with low mood, anhedonia, and psychomotor slowing, the working assumption has generally been that these symptoms reflect a psychological response to changed circumstances, or perhaps a primary depressive episode in a vulnerable individual. A study published in General Psychiatry in early 2026 provides the most detailed longitudinal evidence to date that, in a meaningful subset of patients, this assumption is wrong — and that depression in older adults may instead represent the first legible signal of an ongoing neurodegenerative process.

The finding should give pause to any clinician — whether a psychiatrist in a general outpatient setting or a neuropsychiatrist managing complex presentations — who evaluates depression in patients over sixty. It does not overturn the epidemiology of late-life mood disorder. But it adds a layer of diagnostic obligation that the field has not yet fully codified.

Study at a Glance

Publication: General Psychiatry, 2025; 38(6): e102405

Authors: Christopher Rohde, Martin Langeskov-Christensen, Lene Bastrup Jørgensen, Per Borghammer, Søren Dinesen Østergaard

Design: Retrospective case-control study using Danish national health registers

Sample: 17,711 individuals diagnosed with Parkinson’s disease (PD) or Lewy body dementia (LBD) between 2007 and 2019, matched by age, sex, and calendar year against patients with rheumatoid arthritis, chronic kidney disease, or osteoporosis

Outcome: Incident depression tracked for up to 10 years before and 10 years after PD/LBD diagnosis

The Architecture of the Finding

The methodological strength of the Rohde et al. study lies in its comparison group. The central question was not simply whether depression precedes Parkinson’s disease and Lewy body dementia — that has been observed before, in smaller samples and over shorter time horizons. The question was whether the elevated depression risk seen in this population is qualitatively different from the elevated depression risk seen in other serious chronic conditions. It is.

Patients with rheumatoid arthritis, chronic kidney disease, and osteoporosis were chosen as controls precisely because these are conditions that impose genuine physical burden and can reasonably be expected to generate reactive mood disturbance. If the elevated rate of depression among patients who later receive a PD or LBD diagnosis were simply a function of illness burden, the pattern should look roughly similar across groups. It does not. Depression rose steadily in the decade preceding a PD or LBD diagnosis, peaking in the three years immediately before diagnosis. It then remained persistently elevated in the years after diagnosis — again, at rates higher than those seen in the comparison chronic illness groups. The authors describe the pattern in pre-diagnostic depression as indicative of early neurodegenerative change rather than psychological reaction.

For neuropsychiatrists, this distinction is not merely academic. It reframes the diagnostic encounter. A 64-year-old presenting with a first episode of depression — no prior psychiatric history, no obvious precipitant, perhaps some mild psychomotor features that the clinician has attributed to depressive slowing — may be presenting with a prodromal neurological condition. The psychiatric symptom is real, and it warrants treatment. But it may also be evidence, pointing toward a diagnosis that has not yet declared itself through its more recognizable features.

“Depression in the prodromal phase of Parkinson’s disease and Lewy body dementia may reflect early neurodegenerative changes in the brain rather than being only a psychological reaction to declining health.”

— Rohde et al., General Psychiatry, 2026

Why Lewy Body Dementia Demands Separate Attention

One of the study’s more clinically important findings concerns the differential profile between Parkinson’s disease and Lewy body dementia. Depression rates were higher in LBD than in PD — both in the pre-diagnostic period and following diagnosis. This is not surprising given what is known about the neurobiology of the two conditions, but it carries implications that have not yet penetrated routine clinical practice.

Lewy body dementia remains one of the most frequently misdiagnosed conditions in geriatric psychiatry and neurology. The Parkinson’s Foundation estimates that over half of people living with atypical parkinsonism disorders are initially diagnosed with Parkinson’s disease, and an accurate diagnosis can take up to three years from symptom onset. For patients presenting to a psychiatrist — as many with LBD do, given the prominence of psychiatric features including depression, anxiety, visual hallucinations, and fluctuating cognition — misattribution to a primary mood or psychotic disorder is common and well-documented.

The neurobiological basis for this depression burden in LBD relates to where Lewy bodies — the aggregates of misfolded alpha-synuclein protein — develop first. Research published in Communications Biology in early 2026 clarified that when Lewy bodies form in the brainstem, the initial interference is with systems governing autonomic regulation, sleep, mood, and pain — not yet with the substantia nigra pathways that produce the characteristic movement symptoms of Parkinson’s disease. A patient whose brainstem is accumulating alpha-synuclein aggregates may be depressed, dysautonomic, and sleep-disturbed for years before a single clinical feature of parkinsonism or dementia appears. That patient is likely to present first to a psychiatrist, not a neurologist.

Clinical Implications for Psychiatrists and Neuropsychiatrists

The Problem of the Attributional Default

The challenge the Rohde study poses is not primarily diagnostic — there is no validated biomarker-based screening test that a NYC psychiatrist or neuropsychiatrist can currently deploy to identify a patient with prodromal Parkinson’s disease or LBD in a routine outpatient evaluation. The challenge is attitudinal. Late-life depression, particularly first-episode depression in a patient with no prior psychiatric history and no compelling psychosocial precipitant, has historically been attributed to either primary affective illness or the generic emotional weight of aging. Both attributions may be incorrect.

The study’s authors are explicit on this point. Their recommendation is not that every older adult with depression be referred for neurological workup. It is that clinicians cultivate heightened awareness of associated features — subtle motor signs, REM sleep behavior disorder, visuospatial difficulties, fluctuating cognition, autonomic symptoms — that might indicate the depression exists within a broader neurological context. In settings where a NYC neuropsychiatrist is involved in the evaluation, this integrated attentiveness is more structurally available; in standard psychiatric outpatient practice, it requires a deliberate expansion of the clinical interview.

REM sleep behavior disorder (RBD) is particularly worth flagging. Studies of prodromal LBD have established that RBD — in which patients physically act out their dreams during sleep, due to loss of normal muscle atonia — is among the strongest early markers of synucleinopathy, and can precede diagnosis by years or even decades. A patient who presents with late-life depression and reports, or whose bed partner reports, episodes of hitting, kicking, or shouting during sleep should prompt serious consideration of a neurological referral.

What This Does Not Mean

The study’s authors are appropriately cautious about the scope of their finding, and so should clinicians be. Depression is common. Parkinson’s disease and Lewy body dementia, while not rare, are not the explanation for the majority of depressive episodes in older adults. The Rohde study establishes a population-level signal — a statistically robust pattern across nearly 18,000 patients — not a one-to-one causal relationship. The authors state clearly that the finding should not be read to mean that every patient with depression will develop Parkinson’s disease or dementia.

Nor does the study resolve the mechanistic question with finality. The working hypothesis — that early neurodegenerative changes in monoaminergic and limbic circuits produce depression as a downstream effect, independent of and prior to the more familiar clinical features of PD or LBD — is well-supported by existing neurobiological literature. But the causal pathway has not been definitively established, and the possibility that shared genetic or environmental risk factors independently predispose individuals to both depression and neurodegeneration cannot yet be excluded.

What the study does establish, with the rigour of a large national register study and a well-chosen comparison group, is that the two phenomena are not simply coincidental, and that their co-occurrence is not adequately explained by emotional response to chronic illness. That is sufficient to warrant a revision of clinical habits — particularly among psychiatrists and neuropsychiatrists who evaluate older patients.

“Following a diagnosis of PD or LBD, the persistent higher incidence of depression highlights the need for heightened clinical awareness and systematic screening for depressive symptoms in these patients.”

— Christopher Rohde, first author, General Psychiatry, 2026

The Post-Diagnostic Period: An Overlooked Problem

One aspect of the study that has received less attention in secondary coverage is its post-diagnostic findings. The elevated rate of depression did not resolve following a diagnosis of PD or LBD — it persisted for the full ten-year post-diagnostic observation window. This is clinically significant for a different reason. Depression in patients already diagnosed with Parkinson’s disease or Lewy body dementia is frequently underrecognized and undertreated. The overlap between the somatic features of depression (psychomotor slowing, fatigue, sleep disturbance, anhedonia) and the features of PD and LBD themselves makes confident diagnosis difficult. Clinicians may attribute low mood to the disease burden itself and forgo active treatment.

The Rohde data suggest that this is a meaningful clinical error. Depression in PD has been associated, in prior research, with accelerated cognitive decline, greater disability, increased caregiver burden, and higher mortality. Treating it as an inevitable and therefore unaddressable feature of the neurodegenerative condition does a disservice to patients. The NYC neuropsychiatrist or psychiatrist managing a patient with established PD or LBD should apply the same rigor to identifying and treating comorbid depression as they would in any other patient population — perhaps more so, given the evidence that its consequences in this group are severe.

Looking Forward

The Rohde study is best understood as a contribution to a longer arc of research that is gradually constructing a prodromal neurology of Parkinson’s disease and Lewy body dementia. REM sleep behavior disorder, anosmia, constipation, and now systematically documented depression — each represents a symptom that the field has come to recognize as a possible early indicator of alpha-synuclein pathology, arising years before the diagnosis that currently defines these conditions.

What the field has not yet produced is a validated, clinically deployable algorithm for identifying which patients with these prodromal features will go on to develop PD or LBD, and on what timeline. That work is underway — in biomarker research, in neuroimaging, and in longitudinal cohort studies — but it is not complete. In its absence, the appropriate clinical posture is one of informed vigilance: treating the depression, documenting the associated features carefully, and maintaining a low threshold for neurological referral when the constellation of symptoms warrants it.

For the psychiatrist or neuropsychiatrist evaluating a first episode of depression in a patient over sixty, this study adds a question to the clinical encounter that has not previously been standard: Is this a mood disorder — or is this a brain that is beginning to change in ways that our current diagnostic categories cannot yet fully capture? The evidence, as it accumulates, suggests we should be asking it more often.

Primary source: Rohde C, Langeskov-Christensen M, Jørgensen LB, Borghammer P, Østergaard SD. Depression preceding and following the diagnosis of Parkinson’s disease and Lewy body dementia. General Psychiatry 2025;38(6):e102405. DOI: 10.1136/gpsych-2025-102405

Additional sources: Jos S et al. Parkinson’s disease-specific α-Synuclein variants potentially drive Lewy body formation by engaging in promiscuous and non-functional interactions. Communications Biology (2026). DOI: 10.1038/s42003-025-09395-9  ·  Parkinson’s Foundation: Dementia with Lewy Bodies  ·  StatPearls: Lewy Body Dementia (2026)

This article is intended for clinicians and informed readers. It does not constitute clinical advice. All treatment decisions should be made in the context of individual patient assessment and current clinical guidelines.

© 2026 PsychiatryNeurology.net

Posted in News | Tagged , , , , , , , , , , |

Aerobic Exercise and Depression: Re-Reading the Evidence in 2026

Posted on February 12, 2026 by Maurice Preter MD

Aerobic Exercise and Depression: Re-Reading the Evidence in 2026

A sweeping global review now ranks aerobic exercise alongside first-line pharmacotherapy for depression. A NYC neuropsychiatrist examines what the data actually supports

Posted on February 12, 2026 by the PsychiatryNeurology.net Team

The claim has been circulating for years — sometimes whispered, occasionally shouted — that exercise might equal medication for depression. In early 2026, that claim received its most comprehensive empirical support to date. An umbrella review published in the British Journal of Sports Medicine synthesized 81 meta-analyses encompassing 1,079 randomized trials and nearly 80,000 participants. Its central finding: aerobic exercise produces reductions in depressive symptoms comparable in magnitude to first-line pharmacotherapy and psychological treatments, with supervised, group-based formats conferring the largest effects. The authors urged that exercise be considered a first-line option, prescribed “with the same confidence as traditional treatments”.

For a neuropsychiatrist treating mood disorders in New York, these are not abstract findings. They land directly in the consulting room, reshaping the conversation with every patient who has not responded adequately to medication or who cannot tolerate side effects. But what does “comparable” actually mean, and where does the evidence fall short? This article re-reads the data as it stands in mid-2026 — not as advocacy, but as clinical clarification. And it does so with a longer lens: the same physiological systems that aerobic exercise recruits against depression are central to cognitive and physical longevity — a connection that restores dimension to the depression conversation, linking treatment of today’s mood to preservation of tomorrow’s brain.

The Evidence Architecture: What the Studies Actually Report

To understand the 2026 consensus, one must trace the evidentiary sequence that led to it.

The pivotal paper was Noetel and colleagues’ 2024 network meta-analysis, published in The BMJ, which examined 218 randomized controlled trials involving 14,170 participants with major depressive disorder. Network meta-analysis allows direct comparison of interventions even when they were not tested head-to-head, and the results were striking: walking and jogging produced moderate-to-large reductions in depression (Hedges’ g = −0.62), as did yoga (−0.55), strength training (−0.49), and mixed aerobic exercise (−0.43) when compared with active control conditions such as usual care or placebo. Critically, effects were proportional to the intensity of exercise prescribed, and exercise appeared equally effective for people with and without comorbidities and across different baseline depression severities.

In parallel, the Heissel systematic review — narrower in scope, encompassing 41 trials and 2,264 participants — reported an even larger pooled effect size (standardized mean difference = −0.946), translating to a number needed to treat of 2. That is a statistic one rarely encounters outside the most definitive pharmacotherapy trials: two people would need to exercise for one to experience a clinically meaningful benefit beyond control conditions.

The 2026 Munro umbrella review then consolidated these and other meta-analyses. The headline figures: exercise was associated with moderate reductions in depressive symptoms (SMD, −0.61; 95% CI, −0.69 to −0.54) across all age groups and clinical contexts studied. Aerobic modalities — running, swimming, cycling — showed the strongest associations for both depression and anxiety outcomes. Group-based and supervised delivery amplified the antidepressant effect, while shorter, lower-intensity formats proved most effective for anxiety.

For a NYC psychiatrist weighing these data against pharmacotherapy, the comparison is instructive. Antidepressant medications routinely produce effect sizes in the range of 0.3 to 0.4 when measured against placebo in regulatory-grade trials — and those effect sizes shrink further when unpublished trials are included. The exercise literature, for all its methodological heterogeneity, converges on effect estimates that are at least as large, and possibly larger, than those supporting many widely prescribed agents.

Mechanism: More Than Endorphins

The popular narrative that exercise lifts mood through endorphins has a kernel of truth but fundamentally misrepresents the biological interface. A 2025 neurobiological review synthesized findings that exercise exerts antidepressant effects through three convergent pathways: modulation of neurotransmitter systems — serotonin, dopamine, GABA receptor subtypes; upregulation of brain-derived neurotrophic factor (BDNF); and enhancement of hippocampal neuroplasticity.

BDNF, in particular, occupies a central position in the mechanistic framework. Regular physical activity reliably increases BDNF levels and hippocampal volume, both of which are diminished in untreated depression. The hippocampus is one of the few brain regions where adult neurogenesis is robustly documented, and aerobic exercise is among the most reliable behavioral promoters of that neurogenesis. This is not an endorphin rush; it is a remodeling of the neural substrate that underlies emotional regulation and declarative memory. And it is here that the depression treatment conversation merges with the science of longevity. BDNF, hippocampal integrity, and neuroinflammation control are not only antidepressant mechanisms; they are the same pillars that protect against cognitive decline, Alzheimer’s pathology, and age-related loss of brain volume. Prescribing exercise for a depressed 45-year-old is, in a very real sense, making a down payment on her cognitive longevity three decades later.

A neuropsychiatrist practicing in New York also considers the anti-inflammatory dimension. Depression is increasingly understood as a condition of low-grade systemic inflammation, with elevated cytokines that cross the blood-brain barrier and alter prefrontal and limbic function. Aerobic exercise reduces circulating inflammatory markers with an effect that rivals or exceeds pharmacological anti-inflammatory interventions. This may partly explain why exercise benefits are not confined to mild depression: inflammation is elevated across the severity spectrum. The same anti-inflammatory effect is a hallmark of interventions that extend healthspan and promote longevity, linking the daily run to a slower biological clock.

What the Evidence Does Not Support

Before prescribing exercise with the confidence that the umbrella review recommends, several evidentiary limitations require acknowledgment.

First, heterogeneity is consistently high across trials. The Heissel review reported I² values that remained elevated even within subgroups, and the Munro umbrella review noted inconsistent definitions of exercise intensity, duration, and modality across constituent studies. An I² above 75% is not disqualifying — it is common in behavioral intervention research — but it signals that the “true” effect varies considerably by population, context, and implementation.

Second, publication bias has been a persistent concern. Small trials with null findings are less likely to be published, and the exercise literature has historically relied on many small trials. When Heissel and colleagues applied bias-correction methods, they concluded that the effects of exercise had actually been underestimated rather than inflated — a finding that contradicts the usual direction of publication-bias concern, but one that underscores how sensitive the evidence base is to analytic decisions.

Third, the Noetel network meta-analysis noted that most included trials were not designed as non-inferiority studies. That is, they did not aim to demonstrate that exercise is not meaningfully worse than a known effective treatment. Post-hoc comparative claims — “exercise compared favorably with antidepressants” — derive from indirect comparisons within a network structure, which carry less inferential weight than a direct head-to-head trial.

For the clinician in a New York office, these are not reasons to dismiss the evidence. They are reasons to calibrate what is promised. A patient with severe melancholic depression who cannot get out of bed is not equivalent to a trial participant who consented to a supervised exercise protocol. The gap between trial conditions and clinical reality — between an exercise physiologist-led group session and a solitary walk in a Northeast winter — is the space where efficacy data can dissolve into practical frustration.

Implementation: The Problem Is Not Efficacy, but Adherence

The most sobering data concern not whether exercise works, but whether patients in real clinical settings will do it. A 2024 survey of mental health professionals found that “no motivation” was identified as the most common patient barrier to exercise participation, endorsed by 56.5% of respondents. A separate meta-analysis of barriers within psychiatric populations identified “low mood” and “stress,” followed by “lack of support,” as the most prevalent obstacles.

The clinical significance of these findings is hard to overstate. Anhedonia and avolition — the core motivational deficits of depression — directly oppose the initiation and maintenance of an exercise regimen. Recommending exercise to a patient with major depression is not like recommending it to someone with normal mood and motivation. The very symptoms that exercise might treat also obstruct its uptake. This is the central clinical challenge that no meta-analysis fully resolves.

Further, mental health professionals themselves cite a lack of formal training in exercise prescription as a barrier. A survey of clinicians in a university psychiatric setting found that “lack of knowledge on the benefits of physical activity” and “lack of formal education or practice in the promotion of physical activity” were among the principal impediments to exercise recommendation. Psychiatrists in New York and beyond are not typically taught how to prescribe exercise — what dose, what intensity, how to titrate, how to manage adherence — in the same way they learn to prescribe sertraline.

The Practice-Level Translation: What a Prescription Looks Like

Given the evidence and its limitations, what constitutes a clinically responsible exercise recommendation for depression in 2026?

The consensus emerging across guidelines — from the Canadian Network for Mood and Anxiety Treatments (CANMAT), which already lists exercise as first-line monotherapy for mild-to-moderate depression, to the 2026 American College of Lifestyle Medicine expert consensus statement affirming exercise as a primary therapy and foundational adjunct — begins to converge on a prescriptive framework.

The broad parameters: aerobic exercise, moderate intensity (conversational pace — the patient can speak but not sing), 30–45 minutes, three times per week, for a minimum of nine weeks. Supervised, group-based formats outperform individual, unsupervised ones for depression. But — and this is critical — sub-guideline doses still produce benefit. A 2025 meta-analysis of 26 trials found that only three studies met the WHO guideline threshold of 150 minutes per week, yet all 30 produced clinically meaningful improvement. Twenty minutes, three times weekly, was sufficient.

What distinguishes the neuropsychiatrist’s approach from a generic wellness recommendation is the integration of this prescription into a broader diagnostic understanding. The patient with depression must be assessed for the specific barriers that will impair adherence: cognitive slowing, amotivation, sleep disturbance, co-occurring anxiety that makes group settings aversive. The exercise prescription, like a medication regimen, must be titrated, monitored, and adjusted based on response. And the frame can be expanded: this is not solely about lifting a depressed mood; it is an intervention that simultaneously retards systemic inflammation, supports brain structure, and promotes a longer healthspan — a longevity strategy as much as a depression strategy.

Where the Field Must Go Next

Three priorities define the next phase of this research.

First, non-inferiority trials directly comparing structured aerobic exercise with first-line pharmacotherapy are overdue. The indirect comparisons in network meta-analyses are compelling but cannot substitute for randomized head-to-head designs that control for expectation effects, attention, and treatment context.

Second, adherence-enhancement research — testing behavioral strategies to bridge the gap between efficacy and real-world uptake — needs to be funded and published at a scale comparable to the outcome research. The best treatment is valueless if patients cannot access it.

Third, mechanistic research that delineates which depressive subtypes respond preferentially to exercise — melancholic versus atypical, early-onset versus late-onset, inflammatory versus non-inflammatory — would allow clinicians to personalize recommendations rather than applying a uniform prescription. Such personalization could also clarify which patients are likely to accrue the most longevity benefits from an exercise prescription.

Frequently Asked Questions

Q: Does the evidence support exercise as a replacement for medication?
Not as a universal replacement. Current data support exercise as a first-line monotherapy option for mild-to-moderate depression and as an evidence-based adjunctive treatment across all depression severities. For severe depression, particularly with melancholic features or suicidal ideation, the evidence base is thinner, and pharmacotherapy or ECT remains first line. The decision to substitute exercise for medication should be individualized, discussed collaboratively, and monitored closely.

Q: What kind of exercise works best?
Walking and jogging are the most extensively studied and consistently effective aerobic modalities for depression. Yoga and strength training also show moderate-to-large effects. The umbrella review data suggest that aerobic exercise — running, swimming, cycling — produces the strongest signal, but the between-modality differences are smaller than the difference between doing something and doing nothing. The optimal exercise is the one the patient will sustain.

Q: How long does it take to feel an effect?
Trials with durations as short as nine weeks have demonstrated significant antidepressant effects, but larger benefits accumulate with longer interventions. The trajectory resembles that of pharmacotherapy more than that of an acute anxiolytic: improvements are gradual, cumulative, and more robust after two to three months of consistent practice.

Q: Is this relevant for treatment-resistant depression?
Yes, with an important caveat. Exercise has been shown to benefit people across depression severity levels and with comorbidities. The 2026 Annals of General Psychiatry meta-analysis of aerobic exercise as an adjunct found a significant moderate effect when added to standardized treatment (SMD = −0.72), with the combination of aerobic exercise and pharmacotherapy showing the largest effect (SMD = −0.97). But patients with treatment-resistant depression are also those for whom motivational deficits are most profound. Adjunctive exercise in this population almost certainly requires supervised, structured, and supported implementation.

Q: Does aerobic exercise also improve longevity outcomes in people with depression?
Although direct trials are limited, the overlap is compelling. Depression is an independent risk factor for cardiovascular disease and all-cause mortality. Aerobic exercise robustly improves cardiovascular fitness, reduces systemic inflammation, and enhances BDNF — all mechanisms linked to extended healthspan. Treating depression with exercise may therefore simultaneously reduce both psychiatric morbidity and long-term mortality risk, giving it a dual role as depression treatment and longevity intervention.

Posted in Aging, Clinical & Theoretical, Complementary - Alternative Medicine, epigenetics, Fifth Avenue Concierge Medicine, Health, Lifestyle Psychiatry, new treatments, News | Tagged , , , , , , , , , , , , , , , , , , |
Maurice Preter MD Psychiatry Neuropsychiatry Neurology

We pride ourselves in providing exceptional quality of care, access, comfort and privacy to our patients.

Contact us

QUICK LINKS

ADDRESS

  • Office of Maurice Preter MD
    242 East 72nd Street, Doctor’s Office 1A
    New York, NY 10021
    United States of America
  • Phone: +1 (212) 713-5336
  • Fax: +1 (212) 713-5336